Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Total Liabilities (2016 - 2025)

Palisade Bio (PALI) has disclosed Total Liabilities for 16 consecutive years, with $3.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 37.87% to $3.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.8 million, a 37.87% increase, with the full-year FY2024 number at $3.4 million, up 23.69% from a year prior.
  • Total Liabilities was $3.8 million for Q3 2025 at Palisade Bio, down from $4.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $24.4 million in Q2 2021 to a low of $1.2 million in Q1 2021.
  • A 5-year average of $4.7 million and a median of $3.1 million in 2022 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: skyrocketed 2712.3% in 2021, then crashed 85.26% in 2022.
  • Palisade Bio's Total Liabilities stood at $12.4 million in 2021, then crashed by 73.42% to $3.3 million in 2022, then fell by 16.6% to $2.7 million in 2023, then increased by 23.69% to $3.4 million in 2024, then increased by 11.01% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for PALI's Total Liabilities are $3.8 million (Q3 2025), $4.0 million (Q2 2025), and $2.9 million (Q1 2025).